CHICAGO — As the global oncology community converges for the annual American Society of Clinical Oncology (ASCO) meeting, the landscape of Metastatic Breast Cancer (MBC) treatment is undergoing a period of rapid, albeit complex, transformation. In a comprehensive update to stakeholders, Dr. Kelly Shanahan, President of METAvivor and a prominent physician-advocate living with MBC, has detailed a surge in research demand, a shift toward patient-centric clinical trial design, and a flurry of regulatory activity that underscores both the progress and the hurdles facing the stage IV community.
At the heart of this update is a call for a fundamental restructuring of how cancer research is funded, evaluated, and executed. From a record-breaking number of grant applications to high-stakes advocacy on the ASCO stage, the current momentum suggests that the "patient voice" is no longer a peripheral consideration but a central pillar of modern oncology.
Main Facts: A Record-Breaking Year for METAvivor
The most immediate indicator of the current research climate is the sheer volume of interest in independent funding. METAvivor, the only U.S. non-profit dedicated exclusively to funding research for stage IV breast cancer, reported receiving 200 Letters of Intent (LOIs) for its current grant cycle. This figure represents a 100% increase over historical averages, matching a similar spike seen in the previous year.
According to Dr. Stuart Martin, a long-standing member of the METAvivor Scientific Advisory Board (SAB), this surge is a direct reflection of the "uncertainty around federal research dollars." As government funding becomes increasingly competitive and focused on broader categories, researchers are turning to specialized organizations like METAvivor to keep high-risk, high-reward metastasis research moving forward.
Furthermore, the organization is doubling down on its "Patient Advocate Reviewer" (PAR) program. This initiative ensures that scientific merit is balanced with patient relevance. By involving those actually living with the disease in the grant-selection process, METAvivor aims to prioritize research that addresses quality of life and survival longevity rather than purely theoretical milestones.
Chronology of Advocacy: A Summer of Strategic Engagement
The months of May and June 2024 represent a critical window for MBC advocacy, characterized by three major milestones:
1. The Grant Review Phase (Late May):
The METAvivor SAB met in late May to distill the 200 LOIs into a shortlist of full applications. This phase is critical for identifying "impactful ideas" that challenge the status quo of metastasis treatment.
2. ASCO 2024 (May 31 – June 4):
At the ASCO conference in Chicago—one of the largest medical gatherings in the world—Dr. Shanahan was invited to deliver a featured address titled “How to design trials that are meaningful to people with cancer: ask us.” The presentation focused on "Patient-Centered Endpoints," arguing that clinical success should be measured by what patients value, such as functional status and duration of response, rather than just radiographic progression.
3. The Hormel Institute Global Cancer Consortium (Mid-June):
Following ASCO, the advocacy efforts move to Minnesota. The focus here shifts to the biological "hallmarks of metastasis." Dr. Danny Welch, a pioneer in metastasis research and an original METAvivor grant recipient, will deliver the keynote. The goal is to bridge the gap between bench science and the lived experience of patients, urging researchers to "build a bigger table" for patient experts.
Supporting Data: The Regulatory Landscape and New Approvals
The month of May saw a significant flurry of activity from the U.S. Food and Drug Administration (FDA), highlighting the rapid pace of drug development in the MBC space.
New Approvals and Indications
- Vepdegestrant (Veppanu): A novel PROTAC (Proteolysis Targeting Chimera) protein degrader, vepdegestrant has shown promise for patients with ER+/HER2- MBC, particularly those harboring the ESR1 mutation. This mutation often makes tumors resistant to standard aromatase inhibitors.
- Datopotamab Deruxtecan (Dato-DXd): Marketed as Datroway, this antibody-drug conjugate (ADC) has been approved as a first-line treatment for patients with metastatic Triple-Negative Breast Cancer (TNBC) who are ineligible for immunotherapy. This provides a critical new option for one of the most aggressive subtypes of the disease.
- Trastuzumab Deruxtecan (Enhertu): The FDA expanded the indications for this "blockbuster" ADC into the early-stage HER2+ setting. The strategic implication is significant: by using more potent treatments earlier, the oncology community hopes to prevent the transition to metastatic disease entirely.
The ESR1 Mutation Debate
One of the most contentious points in recent months involves the SERENA-6 trial and the drug camizestrant. The trial investigated whether switching a patient’s treatment upon the detection of an ESR1 mutation (via circulating tumor DNA) before physical progression appeared on a scan would improve outcomes.
While the European Medicines Agency (EMA) moved toward recommendation, the FDA’s Oncologic Drugs Advisory Committee (ODAC) recently voted against recommending this "early switch" strategy. The committee cited the need for more definitive data on whether moving the goalposts from imaging to molecular markers truly benefits the patient in the long term.
Official Responses: The Call for Patient-Centered Endpoints
Dr. Shanahan’s address at ASCO serves as a formal response to the current structure of clinical trials. The central thesis of her advocacy is that the "expert" status of the patient is currently undervalued.
"To quote the Spice Girls, ‘Yo, I’ll tell you what I want, what I really, really want,’" Shanahan noted in her briefing. This lighthearted reference carries a heavy message: patients often prioritize different outcomes than researchers. While a researcher might focus on a two-month extension of Progression-Free Survival (PFS), a patient might prioritize the ability to travel, reduced toxicity, or the avoidance of "financial toxicity" (the crippling cost of modern care).
METAvivor’s leadership continues to push for "Patient-Centered Endpoints" (PCEs). This involves integrating Patient-Reported Outcomes (PROs) into the primary data used for drug approval. The organization argues that if a drug extends life but destroys the quality of that life, the "benefit" must be re-evaluated through the lens of the person taking the medication.
Implications: The Future of MBC Care and Survival
The implications of these developments are twofold: they offer unprecedented hope for long-term survival while highlighting the systemic gaps that remain.
1. The Shift to Molecular Monitoring:
The debate over camizestrant and ESR1 mutations signals a move toward "liquid biopsies." If the FDA eventually aligns with the EMA’s view, the standard of care could shift from "watch and wait" for a tumor to grow on a scan to "detect and intercept" at the molecular level. This would represent a paradigm shift in how metastatic disease is managed—treating it more like a chronic, monitored condition than an acute terminal illness.
2. The Funding Crisis for Metastasis:
The fact that METAvivor is seeing a 100% increase in grant applications is a double-edged sword. It shows a vibrant community of scientists eager to solve the puzzle of metastasis, but it also reveals a precarious reliance on private philanthropy. Without a corresponding increase in federal funding specifically earmarked for metastatic (rather than primary) cancer, many promising therapies may never make it out of the lab.
3. The Role of ADCs:
The approvals of Dato-DXd and the expansion of Enhertu confirm that Antibody-Drug Conjugates are the current "gold rush" in oncology. These "smart bombs" deliver chemotherapy directly to cancer cells, sparing healthy tissue. The implication for patients is a potential reduction in the systemic side effects that have historically characterized cancer treatment.
Conclusion
As Dr. Shanahan prepares for her own clinical trial scans in Nashville—a poignant reminder that those leading the advocacy are also those fighting for their lives—the message from METAvivor remains clear. The progress in May and June 2024 demonstrates that the "dim" of metastatic cancer can change quickly, but the trajectory is increasingly toward precision medicine and patient empowerment.
The oncology community now stands at a crossroads: it must decide whether to continue with traditional metrics of success or to embrace a new era where the "Spice Girls" approach—asking the patients what they really want—becomes the standard for scientific excellence. For the hundreds of thousands living with MBC, the answer to that question is not just a matter of policy, but a matter of time.
About the Author
